Clinical Trials Logo

Filter by:
NCT ID: NCT05993429 Recruiting - Cholangiocarcinoma Clinical Trials

Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma

Start date: August 14, 2023
Phase:
Study type: Observational

This is an observational study with a prospective cohort design. This study enrolled patients with suspected hilar cholangiocarcinoma on imaging. This study aims to evaluate the histopathological diagnostic efficacy of endoscopic ultrasound-guided fine-needle aspiration/biopsy (EUS-FNA/B) and endoscopic retrograde cholangiopancreatography (ERCP) with or without peroral cholangioscopy targeted biopsy (POCS-TB) in patients with suspected hilar cholangiocarcinoma. In addition, the incidence of complications was compared between the EUS-FNA/B and ERCP with or without POCS-TB. The impact of the histopathological diagnosis on survival outcomes in patients with suspected hilar cholangiocarcinoma was evaluated.

NCT ID: NCT05993117 Recruiting - Clinical trials for Drug-Refractory Epilepsy

Rechargeable Implantable Vagus Nerve Stimulation System for Drug-Refractory Epilepsy

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the performance of automatic stimulation mode of a new rechargeable implantable vagus nerve stimulation system for drug-refractory epilepsy

NCT ID: NCT05993078 Recruiting - Brain Infarct Clinical Trials

Normal Saline Infusion for Stroke After Intravenous Thrombolysis

NS-STAR
Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

This study aims to explore the safety and efficacy of 0.9% normal saline (NS) infusion on stroke after intravenous thrombolysis (IVT), we decided to conduct this multi-centre randomized controlled trial for the first time. This trial will provide an innovative strategy to facilitate functional independence after stroke administered with IVT. This is a multi-center, randomized controlled two arm (1:1 ratio) clinical trial. The enrolled participators will be divided into NS group and control group randomly after confirming as acute ischemic stroke (AIS) according to symptoms and signs. In NS group, the patient will undergo NS 2000ml intravenous infusion swiftly after IVT, with the speed of 200ml/h. In control group, the patient will not undergo NS intravenous infusion after IVT. The primary efficacy is disability at days 90, as scored by means of the modified Rankin scale (mRS), dichotomized as a favorable outcome (a score of 0 or 1), or an unfavorable outcome (a score of 2 to 6). The secondary outcomes mainly comprise neurological deficits, disability, imaging and laboratory tests at each follow-up time. The safety outcomes include the cerebral edema at 24-hour post-IVT detected by cranial CT, the 24-hour fluctuation of blood pressure and the cardiac function detected by ultrasonic cardiogram within 3 days after IVT. Stata 15.1 and R software will be used for statistical analysis

NCT ID: NCT05992974 Recruiting - Clinical trials for Gestational Diabetes

To Identify Urinary Biomarkers Associated With Gestational Diabetes Mellitus [GDM]

Start date: August 31, 2023
Phase:
Study type: Observational

Gestational diabetes mellitus(GDM) is one of the most common complications of pregnancy. The incidence of GDM is higher in Asian than in other regions, and GDM can increase the risk of a series of perinatal complications. The investigators has been committed to the early diagnosis of GDM, and several biomarkers in the first trimester and urinary proteomic markers that were associated with GDM have been found. Based on the previous work, the aim of this study was to verify the predictive ability of urinary proteomic markers for GDM that has been found in the previous study of the researchers. This study is a multi-center, prospective, and observational study. Urine samples will be collected twice, at 12 weeks and 24-28 weeks of gestation, respectively.

NCT ID: NCT05992870 Recruiting - Breast Cancer Clinical Trials

Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction

Start date: July 8, 2023
Phase: N/A
Study type: Interventional

Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstruction are rare. Some studies have shown that NART followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. It's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.

NCT ID: NCT05992701 Recruiting - Parkinson's Disease Clinical Trials

Effectiveness and Safety of Directional Deep Brain Stimulation for Parkinson's Disease

Start date: July 28, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of the PINS Deep Brain Stimulation (DBS) system, including the G107R/G107 IPG, L305/L306 directional leads, E204 extensions and related system components.

NCT ID: NCT05992597 Recruiting - Clinical trials for Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the remission rate and prognosis of patients with induction therapy.

NCT ID: NCT05992584 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Start date: August 10, 2023
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).

NCT ID: NCT05992285 Recruiting - Insomnia Disorder Clinical Trials

A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Insomnia disorder (ID) is a significant public health problem worldwide, with nearly a third of the general population experiencing insomnia symptoms in their lifetime. Therefore, finding a safe, effective, and easy-to-use non-pharmacological method for treating ID is urgent. Repetitive transcranial magnetic stimulation (rTMS) has been used to varying degrees in many neurological and psychiatric diseases and has broad application prospects for treating ID.θ-burst stimulation is characterized by cluster stimulation.Continuous stimulation (cTBS) mainly has inhibitory effects on the cortex. The inhibition of motor-evoked potentials can last for 60 minutes, which is longer-lasting, has a lower stimulation intensity, and is shorter in duration than traditional rTMS. There are no reports on clinical studies of cTBS treatment for ID. So far, sleep research has mainly focused on the interconnections between the neocortex and subcortical structures, while cerebellar activity has been largely overlooked.The mechanism of rTMS treatment for insomnia with the cerebellum as the target is unclear. This study proposes to apply cTBS mode to the cerebellar dentate nucleus for rTMS treatment in patients with ID to explore its effectiveness and safety in improving insomnia disorder.

NCT ID: NCT05991973 Recruiting - Clinical trials for T Lymphoblastic Leukemia/Lymphoma

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.